Jasper Therapeutics to Merge with Amplitude Healthcare Acquisition Corporation to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
Palo Alto – Paul Hastings LLP, a leading global law firm, announced today that the firm served as legal advisor to Jasper Therapeutics, Inc. (Jasper Therapeutics) in its agreement to merge with Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company (SPAC).
The merger will result in Jasper Therapeutics becoming a publicly listed company. The combined company will be named Jasper Therapeutics Inc. and is expected to remain listed on Nasdaq and trade under the new ticker symbol “JSPR.” Amplitude Healthcare Acquisition Corporation trades under the symbol “AMHC.”
Jasper Therapeutics is a biotechnology company focused on hematopoietic cell transplant therapies. The company expects to use the cash resources of the combined company following the merger and PIPE to support the clinical development of JSP191, a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft.
The Paul Hastings team included Jeff Hartlin and Jason Rabbitt-Tomita (Mergers and Acquisitions), Samantha Eldredge (Securities and Capital Markets), Scott Flicker (Regulatory), Dan Stellenberg (Employment), Todd Schneider (Corporate/IP), Mike Haun (Tax), of counsels Jeffrey Ii and Amy Lawrence, and associates, Laura Yip, Quinn Dang, Tiffany Jones, Matt Savoff, Derek Rogers and Mia Zhang.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.